Connected With Latham

Stakeholders from across the healthcare industry recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2026. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott discusses key takeaways from the conference with Amanda Forys, Managing Partner at Magnolia Market Access, and Sabrina Aery, Founder at Aery Policy & Access Partners. Topics include Most Favored Nation pricing developments, the evolving 340B landscape, Average Sales Price reporting, and the implementation of the Inflation Reduction Act.

Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in y...

Built on a foundation of deep fundamental research and data-driven insights, Maverick Capital manages over US$15 billion across three distinct pillars: Public Equities, Ventures, and Silicon. Since launching in 2015, Maverick has backed breakout companies in healthcare, biotech, and technology from seed stage through IPO, including SiMa.ai and TensorWave. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Trevor Wiessmann, General Counsel and Chief Compliance Officer at Maverick Capital, to explore Trevor's journey from published novelist to overseeing legal and compliance at a US$15 billion-plus firm, the in...

The US Physician Payments Sunshine Act requires life sciences companies to publicly report payments, transfers of value, and ownership interests. In the first episode of our Shining a Light on the Sunshine Act and Transparency Requirements series, Washington, D.C. counsel Nicole Liffrig Molife and associate Megan Lich walk listeners through the fundamentals of Sunshine Act compliance, including who is required to report, what types of payments and ownership interests must be reported, and key deadlines and compliance strategies.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does n...

The Centers for Medicare & Medicaid Services (CMS) proposed the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to coordinate FDA device approval and Medicare coverage decisions under one coordinated process from the start — aiming to shrink a historically five-year gap to as few as 60-90 days. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Nate Beaton, along with associate Danny Machado, break down how RAPID works, how it differs from prior coverage initiatives, and what device manufacturers should consider as the pathway takes shape.

Also check out our bi...

San Francisco-based venture capital firm Brave Capital partners with companies from pre-seed through growth equity stages, backing transformative technology startups in sectors ranging from AI to aerospace and energy. The firm backs modern defense disruptors — known as "neoprimes" — that bridge the traditional military-industrial gap, with investments in companies such as Shield AI. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Ernestine Fu Mak, Founder and Managing Partner of Brave Capital, to discuss the firm's approach to investing in decisive technologies, macro trends shaping AI and infrastructure, capit...

Hercules Capital provides senior secured loans to high-growth, venture capital-backed companies across technology and life sciences. Since its inception in 2003, Hercules has committed more than US$28 billion to more than 700 companies and works with more than 1,000 leading venture capital and private equity firms. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Scott Bluestein, Chief Executive Officer and Chief Investment Officer of Hercules Capital, to discuss Hercules' investment approach, the role of venture debt in the current market, and how AI could shape the future of technology an...

Europe has entered the collective redress era. The full implementation of the EU Representative Actions Directive, coupled with a surge in litigation funding, has transformed the ability of claimant groups to coordinate across jurisdictions. Companies now face the prospect of parallel consumer, data privacy, and competition actions that are global in scope — which means the challenge for defendants is not just winning individual cases, but managing consistency of arguments, data strategies, and settlement approaches across multiple fronts. In this episode of Connected With Latham, London partners Oliver Middleton and Nell Perks and Hamburg partner Christoph Baus discuss how the EU...

California-based venture capital and growth firm with more than US$3 billion under management, NewView Capital invests in high-potential technology companies on a primary, secondary, or hybrid basis. Founded in 2018, NewView has emerged as an early leader in the secondary market, taking a boutique, high-conviction approach to backing category-defining companies. Latham has advised NewView on a range of primary, secondary, and hybrid investments across the US and around the world. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with NewView Capital Partner Ankit Sud to discuss the firm's th...

Residential real estate platform Opendoor puts homeowners in control by replacing the traditional, passive home-selling process with a streamlined e-commerce system. Founded in 2014, Opendoor has since expanded its reach across the lower 48 states, building out a partner network and tackling the complex ecosystem of utilities, title, escrow, and mortgage that surrounds every home sale. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Christy Schwartz, Opendoor's Chief Financial Officer, and Rishi Kotiya, Head of Legal and Corporate Secretary, to discuss how OpenDoor is modernizing the home-selling experience at...

The corporate venture capital arm of Rakuten Group, Rakuten Capital invests in innovative startups across fintech, AI, and other high-growth sectors. Since its founding in 2014, Rakuten Capital has invested in companies like Lyft, Pinterest, Careem, and Upstart, establishing itself as a distinctive force in corporate venture investing. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Saemin Ahn, Managing Partner of Rakuten Capital and Executive Officer of Rakuten Group, to discuss Rakuten Capital's investment thesis, its approach to AI infrastructure and energy, and the art of diplomatic c...

Founded in 2020, Axiado deploys hardware-anchored, AI-driven platform security by embedding silicon directly on the rack, protecting AI and cloud infrastructure against cyberattacks in real time. Latham represented Axiado in its oversubscribed US$100+ million Series C+ funding round. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Gopi Sirineni, Founder, President, and CEO of Axiado, to discuss the company's proximity-based security approach, the evolving cybersecurity landscape for AI infrastructure, and India's growing role in the global semiconductor ecosystem.

This podcast is provided as a se...

Celera Semiconductor aims to radically accelerate the development of analog semiconductor chips using AI. Founded in 2018, Celera has raised US$34 million in funding, including a recent Series A led by Maverick Silicon that Latham advised on. The company partners with the world's largest independent analog fab to engage customers in high-growth industries like data centers, consumer electronics, and industrial components. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Celera's Chief Executive Officer, Patrick Brockett and Chief Operating Officer, Alberto Viviani, to discuss the technology breakthrough behind...

The Trump administration has advanced many policy initiatives in the drug pricing and market access area, and CMS —the Centers for Medicare & Medicaid Services — is the agency at the heart of many of these efforts. Rujul Desai, Senior Counselor to CMS and former Deputy General Counsel at the Department of Health & Human Services, joins Washington, D.C. partner Chris Schott and associate Danny Machado for an update on key CMS priorities. Rujul also discusses the transition from big law to government and shares practice pointers for engaging with the agency.

Also check out our bi-weekly Drug P...

Washington, D.C. partner Chris Schott, and associates Danny Machado and Evan Rothkoff, share observations and insights from the recent Centers for Medicare & Medicaid Services (CMS) Quality Conference and the American Health Law Association's Institute on Medicare and Medicaid Payment Issues conference. They also discuss updates that government speakers shared at these events.

Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an...

A-Frame Brands identifies emerging signals in culture, consumer behavior, and category white space — then moves fast to bring the right products to shelf. They work two ways: co-creating private-label and exclusive product lines with the world's leading retailers, building a portfolio of standalone brands with world-class talent partners across beauty, personal care, fragrance, home care, and pet care. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with A-Frame's Founder and CEO, Ari Bloom, to discuss A-Frame's business model, how the company has evolved, and what draws retailers an...

Over two decades, more than 350 Latham lawyers have taken on Holocaust reparations matters, helping Holocaust survivors apply for pensions for work performed in Nazi-controlled ghettos during World War II. In this episode of Connected With Latham, Laura Atkinson-Hope, Public Service Counsel and Director of Global Pro Bono at Latham, sits down with Anna Bravo, Attorney Support Manager and longtime leader of the firm's Holocaust reparations program, and Isabelle Sarfati, the daughter of a Holocaust survivor client. Together, they reflect on the completion of Latham's final reparations case in 2025, the challenges survivors faced in documenting their experiences, and how Isabelle's...

ParaFi Capital is an alternative asset management and technology firm focused on blockchain and digital assets. Founded in 2018, the firm was among the earliest institutional investors in the blockchain industry and has evolved into a trusted partner to leading institutions around the world. Latham has advised ParaFi on a range of strategic investments across the digital asset ecosystem, including venture financings and DeFi transactions. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with ParaFi's Founder and Managing Partner, Ben Forman, and Chief Operating Officer and Partner, Adrian Ub...

Founded in 2013, Fetch is a daily rewards destination for consumers and brands, turning everyday actions like shopping, dining out, and playing games into tangible value for consumers while delivering measurable advertising for consumer, retail, and restaurant brands. Latham represented Fetch on a series of strategic growth financing transactions in 2025. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Fetch's Chief Financial Officer Gideon Oppenheimer and General Counsel Dave Toomey to explore macro shifts in advertising, capital allocation tradeoffs, expansion into new verticals like fitness and health, and...

States continue to expand their review of healthcare transactions involving private equity, real estate investment trusts, management services organizations, and other investors. Join Washington, D.C. counsel Nicole Liffrig Molife, Los Angeles counsel Yanyan Zhou, and Washington, D.C. associate Margaret Rote as they discuss how the increased level of state regulatory oversight affect health services transactions and key takeaways for investors looking to purchase healthcare companies this year.

Also check out our report: US State Regulatory Spotlight on Healthcare Transactions: Reflections From 2025

This podcast is provided as a service of La...

The drug pricing and market access policy space saw a lot of change in 2025, and the pace is not slowing down. In this episode of Connected With Latham, pharmaceutical industry veteran Sabrina Aery, founder of Aery Policy and Access Partners, joins Washington, D.C. partner Chris Schott and associate Danny Machado for a wide-ranging discussion of key 2025 takeaways and what to expect in 2026.

Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as a service of La...

In this episode of Connected with Latham, complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2026" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the key trends for financial services firms in 2026. Amongst other topics, they discuss the Leeds Reforms, the ESG landscape, and enforcement trends.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make e...

The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pharmaceutical industry veteran with experience in Big 4, brand drugs, biosimilars, and generics, and most recently Vice President of Revenue Finance, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss how organizations can best respond to the changing environment. As Mike explains, think of meeting the challenge as a loop that connects the business, compliance, and legal in a cross-functional collaboration...

Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "plausible mechanism" pathway for personalized therapies, and new draft guidance aimed at streamlining biosimilars and interchangeables. Join Washington, D.C. partner Nathan Beaton and counsel Monica Groat and Chad Jennings as they discuss how these moves differ from traditional policy-making, as well as the practical implications for pricing, manufacturing, M&A, and litigation risk in the healthcare and life sciences industry.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this p...

Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected With Latham, Eliza Biedziak, Managing Director at Ernst & Young LLP, joins Washington, D.C.  partner Chris Schott and associate Danny Machado to explore how these assessments are conducted, the compliance benefits they offer, and the strategic insights they can provide. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as...

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns...

Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott, counsel Nicole Liffrig Molife, and associate Danny Machado share impressions and key takeaways from the conference, including action items like readying litigation support to address likely future challenges. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as a service of La...

In this episode of Connected With Latham, London partner Fiona Maclean, Paris partner Jean-Luc Juhan, and London counsel Alain Traill discuss significant new switching requirements due to take effect for data processing services under the EU Data Act.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, w...

In this episode of Connected With Latham, London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means for data privacy and cybersecurity practices.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any o...

In this episode of Connected with Latham, London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services sector, and key takeaways for financial services firms.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any o...

Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham, Allan Thoen, Director & Associate General Counsel with Sandoz, joins Washington, D.C. partner Chris Schott and associate Danny Machado to discuss impressions and takeaways from the conference. And read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this p...

Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Nate Beaton, and Bill McConagha, and associate Danny Machado share their key takeaways from the meeting, including compliance hot topics and what the industry can expect in terms of regulatory enforcement in 2025. Read our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions i...

The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Ben Haas, and Bill McConagha analyze these FDA implications, and explore how the EO overlaps with five drug pricing bills championed by Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa). Also check out Chris's interview with Life Sciences IP Review about industry impacts of the Grassley bills. And yes, it's back: Read our bi-weekly Drug Pricing Digest on the we...

Founded in 2015, Shield AI uses technology and intelligence systems to protect service members and civilians. The venture-backed unicorn's flagship autonomy software, Hivemind, powers aircraft, drones, and other platforms to reliably support complex missions in contested environments. Latham represented Shield AI on its US$240 million strategic funding round, raising the company's valuation to US$5.3 billion, in March 2025. In this episode of Connected with Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, engages in a dynamic conversation with Shield AI's Chief Financial Officer Kingsley Afemikhe and Chief Legal and Information Officer Jim Carlson. They discuss Shield AI's...

The initial months of the Trump administration have been marked by a flurry of executive orders and significant activity by the Department of Government Efficiency (DOGE). The US Food and Drug Administration is a key target of these efforts. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Ben Haas and associate Danny Machado explore how FDA may be affected, particularly as it relates to novel tobacco and nicotine products, which can be a bellwether for approval and enforcement trends more generally.

This podcast is provided as a service of La...

Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Jason B. Caron and associate Danny Machado share key takeaways from the conference, including a renewed optimism from the dealmaking world and the healthcare policy outlook under the new Trump administration.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and yo...

The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the EU market and impacts a broad range of third-party providers of technology-related services. In this episode of Connected with Latham, Christian McDermott and Alain Traill explore the key changes introduced by DORA, its broad territorial scope, the types of entities that will be impacted, and what compliance is likely to involve for each of them.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create a...

In this episode of Connected with Latham, the final of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the key cross-sector trends for financial services firms in 2025. They provide their thoughts on what firms need to be thinking about in relation to the use of AI, and the continuing importance of ESG.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and La...

In this episode of Connected with Latham, the second of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the upcoming reform agenda for retail markets in 2025. They break down the difficult challenge of balancing risk-taking and growth with consumer protection, what is next for the Consumer Duty, and the progress on reforms to the consumer credit and consumer investment regimes.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not c...

In this episode of Connected with Latham, the first of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss what will likely appear on the reform agenda for wholesale markets in 2025. They examine capital markets reforms, changes to the remuneration rules and SMCR, and ongoing work on repealing and restating MiFID II.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & W...

In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio's Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian Stephenson. Since 2015, BridgeBio, a commercial-stage biopharmaceutical, has maintained a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. Latham has been involved with BridgeBio since its inception, representing BridgeBio on multiple fronts, including recently the company's US$1.25 billion cross-border capital financing, one of the largest private capital financings in life sciences in the last five years and...